Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy
Bioconjugate Chemistry · 17.07.2024 · 35 (7) · 867-882
DOI: 10.1021/acs.bioconjchem.4c00242 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, online erschienen am 26.06.2024. Verfasst von Jialei Hao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Functional Polymer Materials (Ministry of Education), College of Chemistry, Nankai University, Tianjin 300071, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Tumor-Associated Macrophages. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer immunotherapy has yielded remarkable results across a variety of tumor types. Nevertheless, the complex and immunosuppressive microenvironment within solid tumors poses significant challenges to established therapies such as immune checkpoint blockade (ICB) and chimeric antigen receptor T-cell (CAR-T) therapy. Within the milieu, tumor-associated macrophages (TAMs) play a significant role by directly suppressing T-cell functionality and fostering an immunosuppressive environment. Effective regulation of TAMs is, therefore, crucial to enhancing the efficacy of immunotherapies. Various therapeutic strategies targeting TAM modulation have emerged, including blocking TAM recruitment, direct elimination, promoting repolarization toward the M1 phenotype, and enhancing phagocytic capacity against tumor cells. The recently introduced CAR macrophage (CAR-M) therapy opens new possibilities for macrophage-based immunotherapy. Compared with CAR-T, CAR-M may demonstrate superior targeting and infiltration capabilities toward solid tumors. This review predominantly delves into the origin and development process of TAMs, their role in promoting tumor growth, and provides a comprehensive overview of immunotherapies targeting TAMs. It underscores the significance of regulating TAMs in bolstering antitumor therapies while discussing the potential and challenges of developing TAMs as targets for immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Key Laboratory of Functional Polymer Materials (Ministry of Education), College of Chemistry, Nankai University, Tianjin 300071, China.
- State Key Laboratory of Medicinal Chemical Biology, College of Chemistry, Nankai University, Tianjin 300071, China.
ORCID-Profile: Yang Liu
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Hao, J., Zhao, X., Wang, C., Cao, X., & Liu, Y. (2024). Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy. Bioconjugate Chemistry, 35(7), 867-882. https://doi.org/10.1021/acs.bioconjchem.4c00242
Vancouver
Hao J, Zhao X, Wang C, Cao X, Liu Y. Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy. Bioconjugate Chemistry. 2024;35(7):867-882. doi:10.1021/acs.bioconjchem.4c00242
BibTeX
@article{Hao2024,
author = {Hao, Jialei and Zhao, Xinzhi and Wang, Chun and Cao, Xianghui and Liu, Yang},
title = {Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy},
journal = {Bioconjugate Chemistry},
year = {2024},
volume = {35},
number = {7},
pages = {867--882},
doi = {10.1021/acs.bioconjchem.4c00242}
}
EUVIMED